Catabasis Pharmaceuticals reports Q2 EPS (20c), consensus (23c)
"We are thrilled to have achieved important milestones that enable the Phase 3 PolarisDMD trial of edasalonexent for registration purposes. We are now completing final preparations and expect to initiate the Phase 3 trial in the coming months," said Jill Milne, CEO of Catabasis. "Based on muscle effects and stabilization of function seen with edasalonexent treatment in Phase 2, we believe edasalonexent could fundamentally change the course of Duchenne disease progression and the treatment paradigm. We look forward to advancing edasalonexent into the PolarisDMD trial as we progress towards our goal of making edasalonexent available to all those affected by Duchenne with the hope of enabling patients to maintain their functional abilities longer."